Clinical Trials GPS

A 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naive subjects with Type 2 Diabetes. The total duration of the trial is approximately 29 weeks.

This study is a Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of a New Drug in Subjects with Asthma Inadequately Controlled by Corticosteroids

This study is a Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety and Tolerability of a New Drug in Obese Hyperlipidemic Adults with or without Type 2 Diabetes

This trial is a 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naïve subjects with T2DM inadequately controlled on a maximum tolerated dose or maximum dose according to label of GLP-1.

This study is a Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial to Assess the Safety, Tolerability and Immunogenicity of a new Meningococcal Vaccine When Given in Healthy Subjects Age 11 to 26.

This is a global, multi-center, randomized, placebo-controlled study to evaluate adverse events of special interest in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) treated with a new drug plus standard therapy.

The primary objective of this study is to evaluate the 24-hour spirometric effect (FEV1) of a new drug over a 12-week treatment period in subjects with COPD.

The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo.

The primary objective of this study is to evaluate the efficacy of a new drug compared with a placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe Chronic Lower Back Pain.

The primary objectives of this study are to evaluate the 12-week safety, antiviral activity and tolerability of this new Hep C drug when given in combination with PEG and RIBA as measured by extended rapid virologic response.